Jump to content

Talk:Perindopril

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Brain-penetrating?

[edit]
  • Brain-Penetrating ACE Inhibitors May Be Helpful in Alzheimer's Disease - Perindopril is listed as brain-penetrating drug (PMID 15477567). Could be added to the article. Best regards, CopperKettle 18:12, 18 March 2007 (UTC)[reply]
The right place to add this would be the ACE inhibitors article, and it looks as though someone has just started to do that. David Woolley (talk) 13:21, 18 October 2009 (UTC)[reply]

Needs more depth

[edit]

I get this impression that this article has been based almost entirely on patient information leaflets. I think it needs the following:

  • how the stereo-chemistry of the drug makes it effective as an inbibitor (some images of a 3D model would be useful);
  • as the active drug is actually perindoprilat, the formula, structure, and other chemistry information for that compound;
  • how it differs form other ACE inhibitors.

David Woolley (talk) 13:33, 18 October 2009 (UTC)[reply]

Hello, can someone help me on this one. I have been on perindopril and have developed a bad dry cough. i have in the last 48 hrs discontinued the drug but my symptoms still persist. how long will the side effect last. Thank you —Preceding unsigned comment added by 58.68.30.210 (talk) 07:06, 3 June 2010 (UTC)[reply]

coversyl side effect

[edit]

There is no mention of losing sensation on genitals, but it happened right after starting to take it and it is still the same after a year of treatment. Is it going to continue? —Preceding unsigned comment added by 99.254.48.75 (talk) 01:58, 27 April 2011 (UTC)[reply]

Trade names need to be verified

[edit]

This article says that Coversyl is the trade name for perindopril arginine, and that Aceon is the trade name for perindopril erbumine. Yet I am holding a prescription of Coversyl in my hand that very definitely says that Coversyl is actually perindopril erbumine. I know that different countries use different trade names quite frequently, but they don't - far as I know - ever change the chemical/scientific names. This bears some investigation by someone more in the know.

Lonita (talk) 22:38, 14 August 2012 (UTC)[reply]

Coversyl originally contained the erbumine form of perindopril here in Australia, but the manufacturer changed the patent to the arginine form (in around 2008 if memory serves) in order to extend the patent term (therefore preventing competing companies from making generic versions). The powers that be ultimately decided that the change was not sufficient to grant the manufacturers a renewed patent term, so the exercise was futile. It is probable that both forms can be found in various regions, depending on what was decided to be most profitable for that region in terms of the local patent laws. This change does not affect how the drug is absorbed or cleared or how it works any way. It is simply a change in the form of molecule that the active drug is paired with. Its confusing for consumers, and in my opinion was a cynical grab for cash by the manufacturer. 59.167.255.139 (talk) 05:05, 4 September 2013 (UTC)[reply]


Different countries patented different salts of perindopril for different drugs. It looks like, in Australia, this information is correct. In Canada and the US, the salts are reversed and it is Coversyl/Coversyl Plus that are made with is the erbumine salt and Aceon that is made with the arginine salt. I think the article would benefit from broader language, such as "Perindopril is a long-acting ACE inhibitor used to treat high blood pressure, heart failure, or stable coronary artery disease[1] in form of perindopril arginine or perindopril erbumine. It is sold under trade names including Coversyl, Coversum, Aceon, and Perindo." 4:18, 15 December 2016

Twice daily dosing?!

[edit]

Can it be used as a twice daily dosing? or it's just once daily dosing?

--Roomstop (talk) 22:20, 10 June 2014 (UTC)[reply]

erbumine

[edit]

What is erbumine? 115.64.142.162 (talk) 00:50, 9 June 2016 (UTC)[reply]